Arcellx, Inc. financial data

Symbol
ACLX on Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
Location
800 Bridge Parkway, Redwood City, CA
State of incorporation
DE
Fiscal year end
December 31
Latest financial report
10-K - Q4 2024 - Feb 27, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 503 % +32%
Debt-to-equity 55.6 % -43.9%
Return On Equity -22.4 % -6.58%
Return On Assets -14.4 % -36.4%
Operating Margin -127 % -56.4%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 54.9M shares +2.69%
Common Stock, Shares, Outstanding 54.3M shares +3.85%
Entity Public Float 2.6B USD +100%
Common Stock, Value, Issued 53K USD +1.92%
Weighted Average Number of Shares Outstanding, Basic 53.6M shares +11.5%
Weighted Average Number of Shares Outstanding, Diluted 53.6M shares +11.5%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 108M USD -2.16%
Research and Development Expense 157M USD +17.4%
General and Administrative Expense 88.4M USD +33.3%
Operating Income (Loss) -138M USD -53.1%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -105M USD -50.3%
Income Tax Expense (Benefit) 2.07M USD +212%
Net Income (Loss) Attributable to Parent -107M USD -51.9%
Earnings Per Share, Basic -2 USD/shares -36.1%
Earnings Per Share, Diluted -2 USD/shares -36.1%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 106M USD -73.2%
Marketable Securities, Current 482M USD +56.7%
Cash, Cash Equivalents, and Short-term Investments 483M USD
Assets, Current 599M USD -16.3%
Property, Plant and Equipment, Net 46.5M USD +8.73%
Operating Lease, Right-of-Use Asset 23.8M USD -12.2%
Assets 711M USD -13.8%
Accounts Payable, Current 2.1M USD -20%
Accrued Liabilities, Current 56.7M USD +210%
Contract with Customer, Liability, Current 59.1M USD +16.9%
Liabilities, Current 125M USD +6.06%
Contract with Customer, Liability, Noncurrent 76M USD -55.5%
Operating Lease, Liability, Noncurrent 46.5M USD -8.46%
Other Liabilities, Noncurrent 8.59M USD
Liabilities 257M USD -24.5%
Accumulated Other Comprehensive Income (Loss), Net of Tax 848K USD +55%
Retained Earnings (Accumulated Deficit) -497M USD -27.6%
Stockholders' Equity Attributable to Parent 455M USD -6.3%
Liabilities and Equity 711M USD -13.8%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -31.9M USD -118%
Net Cash Provided by (Used in) Financing Activities -2.99M USD -103%
Net Cash Provided by (Used in) Investing Activities -207M USD -210%
Common Stock, Shares Authorized 1B shares 0%
Common Stock, Shares, Issued 54.3M shares +3.85%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -242M USD -215%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 108M USD -72.8%
Deferred Tax Assets, Valuation Allowance 137M USD +49.5%
Deferred Tax Assets, Gross 150M USD +44.6%
Operating Lease, Liability 53.9M USD -7.7%
Payments to Acquire Property, Plant, and Equipment 6.43M USD +556%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -107M USD -53.1%
Lessee, Operating Lease, Liability, to be Paid 82.9M USD -13.2%
Property, Plant and Equipment, Gross 55.9M USD +16.5%
Operating Lease, Liability, Current 7.31M USD -2.57%
Lessee, Operating Lease, Liability, to be Paid, Year Two 7.84M USD -7.82%
Lessee, Operating Lease, Liability, to be Paid, Year One 7.61M USD -2.96%
Operating Lease, Weighted Average Discount Rate, Percent 0.1 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 29M USD -17.7%
Lessee, Operating Lease, Liability, to be Paid, Year Three 8.07M USD -7.77%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 200M shares 0%
Unrecognized Tax Benefits 9.58M USD +178%
Lessee, Operating Lease, Liability, to be Paid, Year Four 8.32M USD -7.72%
Operating Lease, Payments 757K USD +267%
Additional Paid in Capital 951M USD +8.75%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization 826K USD +91.2%
Deferred Tax Assets, Net of Valuation Allowance 12.4M USD +6.03%
Share-based Payment Arrangement, Expense 41.8M USD +94%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%